Document is current
Any future updates will be listed below
-
Authors
Sakurai, Masatoshi https://orcid.org/0000-0002-6687-4136
Mori, Takehiko https://orcid.org/0000-0002-8176-4760
Kato, Koji
Kanaya, Minoru https://orcid.org/0000-0002-0035-8657
Mizuno, Shohei https://orcid.org/0000-0002-4405-8808
Shiratori, Souichi https://orcid.org/0000-0002-5528-7112
Wakayama, Toshio
Uchida, Naoyuki https://orcid.org/0000-0001-5952-5926
Kobayashi, Hikaru
Kubo, Kohmei
Amano, Itsuto
Ohta, Takanori
Miyazaki, Yasuhiko
Kanda, Junya https://orcid.org/0000-0002-6704-3633
Fukuda, Takahiro
Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
Kondo, Eisei https://orcid.org/0000-0003-0995-9405
,
Usui, Yoshiaki
Kato, Harumi
Taji, Hirofumi
Mizuno, Shohei
Hayashi, Kiyohito
Nawa, Yuichiro
Hashida, Risa
Hashimoto, Daigo
Goto, Hideki
Kawata, Takahito
Kanaya, Minoru
Ozeki, Kazutaka
Kuriyama, Kodai
Ohbiki, Marie
Imada, Kazunori
Kako, Shinichi
Sakamoto, Kana
Kameda, Kazuaki
Yoshimura, Kazuki
Nitta, Hideaki
Sekiguchi, Yasunobu
Takahashi, Hiroyuki
Sakai, Rika
Mizuta, Shuichi
Takamatsu, Hiroyuki
Shimizu-Koresawa, Risa
Kataoka, Keisuke
Hiramoto, Nobuhiro
Kamijo, Kimimori
Nishikubo, Masashi
Wada, Fumiya
Suzumiya, Junji
Aoki, Kazunari
Watanabe, Mizuki
Jo, Tomoyasu
Toda, Yusuke
Shimazu, Yutaka
Ago, Hiroatsu
Miyazaki, Kana
Aoki, Tomohiko
Kunou, Shunsuke
Izutsu, Koji
Suzuki, Tatsuya
Kim, Sung-Won
Yamasaki, Satoshi
Iida, Hiroatsu
Yoshida, Isao
Yokoyama, Akihiro
Asakura, Yoshitaka
Sakatoku, Kazuki
Ogawa, Hiroyasu
Mitsuhashi, Kenjiro
Okada, Takahiro
Takahashi, Tsutomu
Suzuki, Ritsuro
Fujimoto, Ayumi
Ishida, Fumihiro
Ikeda, Takashi
Yoshitsugu, Kanako
Shiki, Ikue
Yano, Shingo
Kamiyama, Yutaro
Chihara, Dai
Nagata, Akihito
Ebihara, Michiho
Akihito, Shinohara
Kaji, Daisuke
Yamamoto, Go
Morishima, Satoko
Tamura, Shinobu
- License Information
-
More Information
Article History
Received: 8 September 2020
Revised: 25 November 2020
Accepted: 8 December 2020
First Online: 29 January 2021
Compliance with ethical standards
:
: MS received research funding from MSD K.K. and Nippon Shinyaku Co., Ltd. and personal fees from Nippon Shinyaku Co., Ltd., Takeda Pharmaceutical, Eisai Co., Ltd., and Otsuka Pharmaceutical, outside of the submitted work; TM received research funding from MSD K.K., Novartis Pharma, LSI Medience, Medical & Biological Laboratories, Otsuka Pharmaceutical, Kyowa Kirin Co., Ltd., and Asahi Kasei Corporation and personal fees from Pfizer Inc., MSD K.K., Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma, Kyowa Kirin Co., Ltd., Chugai Pharmaceutical, Shionogi & Co., Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai Co., Ltd., and Astellas Pharma, outside of the submitted work; Koji Kato received research funding from Chugai Pharmaceutical, Takeda Pharmaceutical, Kyowa Kirin Co., Ltd., AbbVie, Novartis Pharma, Eisai Co., Ltd., Janssen Pharma, Celgene, and Ono Pharmaceutical, personal fees from Chugai Pharmaceutical, Takeda Pharmaceutical, MSD K.K., Kyowa Kirin Co., Ltd., Janssen Pharma, Celgene, Ono Pharmaceutical, Mundipharma K.K., and Sumitomo Dainippon Pharma, and served in a consulting or advisory role for Novartis Pharma, Eisai Co., Ltd., Janssen Pharma, and Celgene, outside of the submitted work.
